Overview
Personalized tumor neoantigen therapies and AI-assisted drug development
Funding
Amounts as reported; USD estimates shown only when they matchListed 4 funding records.
No chartable funding estimates yet.
4 listed records lack a clear date or positive USD estimate for the chart.
| Date | Amount | Investors | Sources |
|---|---|---|---|
| Aug 1, 2026 | Undisclosed · Series A+ | 北京昌平产业发展投资基金（有限合伙）, 合肥国生未来科转创业投资基金合伙企业（有限合伙）, 安徽洪泰合康一期创业投资基金合伙企业（有限合伙）, 肥西紫蓬创业投资合伙企业（有限合伙） | No source link |
Evidence Anda Biotechnology completes Series A+ financingOn 2026-08-01, according to Xiniu Data, Anda Biotechnology completed Series A+ financing for an undisclosed amount. Investors were lead investor Anhui Hongtaihekang Phase One Venture Capital Fund Partnership (Limited Partnership), participating investor Beijing Changping Industry Development Investment Fund (Limited Partnership), participating investor Feixizipeng Venture Capital Partnership (Limited Partnership), participating investor Hefei Guoshengweilaikezhuan Venture Capital Fund Partnership (Limited Partnership). The company is a developer of personalized oncology neoantigen vaccines. Translated source brief, not a quotation. Check the original before citing. Sources · 0
北京昌平产业发展投资基金（有限合伙）, 合肥国生未来科转创业投资基金合伙企业（有限合伙）, 安徽洪泰合康一期创业投资基金合伙企业（有限合伙）, 肥西紫蓬创业投资合伙企业（有限合伙） | |||
| Apr 10, 2026 | Undisclosed · Equity | 共青城坤元投资合伙企业, 共青城坤元投资合伙企业（有限合伙） | No source link |
Evidence Anda Biotechnology completes equity financing for an undisclosed amountOn 2026-04-10, according to Xiniu Data, Anda Biotechnology completed equity financing for an undisclosed amount. The investor was Gongqingcheng Kunyuan Investment Partnership (Limited Partnership). The company develops personalized tumor neoantigen vaccines. Translated source brief, not a quotation. Check the original before citing. Sources · 0
| |||
| Jul 7, 2025 | Undisclosed · Strategic | 泰格医药 | No source link |
Evidence No source brief is attached to this record. Sources · 0
| |||
| Mar 24, 2025 | Tens of millions · Series A | 力鼎资本, 博通创投, 司南园科, 德丰杰龙脉基金, 浦信资本 | No source link |
Select ▸ on a row to see its source brief and links.
Valuation
Amounts as reported; USD estimates shown only when they matchListed 4 valuation records.
No chartable valuation estimates yet.
4 listed records lack a clear date or positive USD estimate for the chart.
| Date | Amount | Investors | Sources |
|---|---|---|---|
| Aug 1, 2026 | — · Series A+ | 北京昌平产业发展投资基金（有限合伙）, 合肥国生未来科转创业投资基金合伙企业（有限合伙）, 安徽洪泰合康一期创业投资基金合伙企业（有限合伙）, 肥西紫蓬创业投资合伙企业（有限合伙） | No source link |
Evidence Anda Biotechnology completes Series A+ financingOn 2026-08-01, according to Xiniu Data, Anda Biotechnology completed Series A+ financing for an undisclosed amount. Investors were lead investor Anhui Hongtaihekang Phase One Venture Capital Fund Partnership (Limited Partnership), participating investor Beijing Changping Industry Development Investment Fund (Limited Partnership), participating investor Feixizipeng Venture Capital Partnership (Limited Partnership), participating investor Hefei Guoshengweilaikezhuan Venture Capital Fund Partnership (Limited Partnership). The company is a developer of personalized oncology neoantigen vaccines. Translated source brief, not a quotation. Check the original before citing. Sources · 0
北京昌平产业发展投资基金（有限合伙）, 合肥国生未来科转创业投资基金合伙企业（有限合伙）, 安徽洪泰合康一期创业投资基金合伙企业（有限合伙）, 肥西紫蓬创业投资合伙企业（有限合伙） | |||
| Apr 10, 2026 | — · Equity | 共青城坤元投资合伙企业, 共青城坤元投资合伙企业（有限合伙） | No source link |
Evidence Anda Biotechnology completes equity financing for an undisclosed amountOn 2026-04-10, according to Xiniu Data, Anda Biotechnology completed equity financing for an undisclosed amount. The investor was Gongqingcheng Kunyuan Investment Partnership (Limited Partnership). The company develops personalized tumor neoantigen vaccines. Translated source brief, not a quotation. Check the original before citing. Sources · 0
| |||
| Jul 7, 2025 | — · Strategic | 泰格医药 | No source link |
Evidence No source brief is attached to this record. Sources · 0
| |||
| Mar 24, 2025 | — · Series A | 力鼎资本, 博通创投, 司南园科, 德丰杰龙脉基金, 浦信资本 | No source link |
Select ▸ on a row to see its source brief and links.
Revenue
Amounts as reported; USD estimates shown only when they matchNo revenue records are listed yet.
No revenue rows to list.
Team, products & investors
Explore
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
肿瘤新抗原个性化治疗与AI辅助药物研发